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Disease progression and treatment response in data-driven 
subgroups of type 2 diabetes compared with models based 
on simple clinical features: an analysis using clinical trial data
John M Dennis, Beverley M Shields, William E Henley, Angus G Jones, Andrew T Hattersley
Summary
Background Research using data-driven cluster analysis has proposed five subgroups of diabetes with differences in 
diabetes progression and risk of complications. We aimed to compare the clinical utility of this subgroup-based 
approach for predicting patient outcomes with an alternative strategy of developing models for each outcome using 
simple patient characteristics.
Methods We identified five clusters in the ADOPT trial (n=4351) using the same data-driven cluster analysis as 
reported by Ahlqvist and colleagues. Differences between clusters in glycaemic and renal progression were 
investigated and contrasted with stratification using simple continuous clinical features (age at diagnosis for 
glycaemic progression and baseline renal function for renal progression). We compared the effectiveness of a strategy 
of selecting glucose-lowering therapy using clusters with one combining simple clinical features (sex, BMI, age at 
diagnosis, baseline HbA1c) in an independent trial cohort (RECORD [n=4447]).
Findings Clusters identified in trial data were similar to those described in the original study by Ahlqvist and 
colleagues. Clusters showed differences in glycaemic progression, but a model using age at diagnosis alone explained 
a similar amount of variation in progression. We found differences in incidence of chronic kidney disease between 
clusters; however, estimated glomerular filtration rate at baseline was a better predictor of time to chronic kidney 
disease. Clusters differed in glycaemic response, with a particular benefit for thiazolidinediones in patients in the 
severe insulin-resistant diabetes cluster and for sulfonylureas in patients in the mild age-related diabetes cluster. 
However, simple clinical features outperformed clusters to select therapy for individual patients.
Interpretation The proposed data-driven clusters differ in diabetes progression and treatment response, but models 
that are based on simple continuous clinical features are more useful to stratify patients. This finding suggests that 
precision medicine in type 2 diabetes is likely to have most clinical utility if it is based on an approach of using 
specific phenotypic measures to predict specific outcomes, rather than assigning patients to subgroups.
Funding UK Medical Research Council.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction
Type 2 diabetes is a heterogeneous, multifactorial condi­
tion, comprising 90–95% of all cases of diabetes and 
affecting over 400 million people worldwide. There is great 
interest in better characterising the heterogeneity in type 2 
diabetes and in exploiting this heterogeneity to improve 
care and outcomes for individuals with type 2 diabetes.1–3
Ahlqvist and colleagues4 identified five replicable clusters 
of individuals with diabetes in the All New Diabetics in 
Scania (ANDIS) cohort. The smallest cluster was defined 
by the presence of glutamic acid decarboxylase 
autoantibody (GADA), regardless of other characteristics 
(cluster 1: severe autoimmune diabetes [SAID]). Four 
type 2­like clusters were then characterised by the absence 
of GADA positivity and varying degrees of differences in 
age at diagnosis, and baseline measures of BMI, HbA1c, 
and homoeostatic model assessment (HOMA) 2 measured 
insulin resistance and β­cell function. The four type 2 
diabetes clusters were cluster 2, severe insulin­deficient 
diabetes (SIDD); cluster 3, severe insulin­resistant diabetes 
(SIRD); cluster 4, mild obesity­related diabetes (MOD); 
and cluster 5, mild age­related diabetes (MARD). Ahlqvist 
and colleagues showed potentially clinically important 
differences in disease progression and risk of complications 
between the clusters in observational follow­up, most 
notably a striking increase in the risk of diabetic kidney 
disease in cluster 3 (SIRD).
The key question for any subgroup analysis is the 
clinical utility of the subgroups, and in particular whether 
the proposed subgroups differ in response to therapy, 
which could help to inform treatment strategies.2 
Ahlqvist and colleagues suggested but did not show that 
the clusters could be useful to guide choice of therapy.5 
The only stratified approaches in type 2 diabetes showing 
large differences in response between treatments have 
used subgroups defined by routine clinical measures 
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such as sex and BMI.6 A further key question, raised by 
van Smeden and colleagues7 in response to the original 
study, is whether assigning individuals to clusters has 
greater clinical utility for predicting outcomes than an 
approach that combines continuous clinical features to 
predict outcomes for individual patients.
We aimed to establish the clinical utility of the clusters 
by analysing two large existing trial datasets of 
individuals randomised to metformin, sulfonylurea, and 
thiazolidinedione therapy, ADOPT and RECORD.8,9 By 
contrast with the observational follow­up by Ahlqvist and 
colleagues,4 these trial datasets provided protocol­driven, 
randomised follow­up to assess clinical outcomes and 
differences in response to therapy. We compared the 
utility of the data­driven clusters with simpler approaches 
based on routine clinical measures available in any 
diabetes clinic.
Methods
Study population
The primary study population comprised newly 
diagnosed, drug­naive, individuals with type 2 diabetes, 
recruited between April, 2000, and June, 2002, followed 
up until June, 2006, who had participated in the ADOPT 
trial of glycaemic durability, randomly assigned 
to metformin, sulfonylurea (glibenclamide), or 
thiazolidinedione (rosiglitazone) monotherapy for up to 
5 years (n=4351).8 Eligibility criteria at screening included 
age 30–75 years, fasting plasma glucose 7–13 mmol/L, 
and no evidence of renal impairment (serum creatinine 
>114 μmol/L for men or >106 μmol/L for women). As a 
replication dataset we used participants in the RECORD 
study9 (n=4447), a cardiovascular outcomes trial in 
individuals with established type 2 diabetes (mean 
duration of diabetes 7·1 [SD 4·9] years), initiating the 
same drug classes as in ADOPT but as dual second­line 
therapy, for up to 6 years. Sulfonylurea type was chosen 
on the basis of local practice (glibenclamide [18%], 
gliclazide [30%], or glimepiride [52%]) and rosiglitazone 
was the thiazolidinedione used. Eligibility criteria 
included age 40–75 years, BMI greater than 25·0 kg/m², 
HbA1c 7·0–9·0% (53–75 mmol/mol), and no evidence of 
renal impairment (serum creatinine >130 μmol/L) for 
men and women.
We followed up individuals from ADOPT and RECORD 
from randomisation until the earliest of: the primary 
outcome of the original trial, censor date, 5 years, or the 
occurrence of an outcome of interest. Full individual­
level trial data were accessed through Clinical Trial Data 
Transparency Portal (Proposal 930).
Procedures
In ADOPT we calculated HOMA2 measures of insulin 
resistance and β­cell function with fasting C­peptide and 
fasting­glucose measures using the HOMA2 calculator.10 
GADA positivity (yes or no) was measured using a 
commercially available radioimmunoassay.11 In RECORD, 
we calculated HOMA2 measures using fasting insulin 
because data on fasting C­peptide were not available. 
GADA was not measured. Sex, age at diagnosis, baseline 
Research in context
Evidence before this study
A study by Ahlqvist and colleagues proposed a novel stratification 
method for patients with diabetes, using a data-driven cluster 
analysis in Scandinavian registry data to identify five reproducible 
subgroups of adult-onset diabetes. The authors showed 
differences between the clusters in disease progression and risk of 
complications in observational follow-up. The authors suggested 
the clusters might help with therapy selection in the future but 
did not test whether the clusters could inform therapy choice. 
We searched Scopus, Web of Science, and Google Scholar for 
citations of the original study, searching for follow-up studies 
assessing the reproducibility, clinical utility, and role in treatment 
selection of the proposed data-driven clusters up to Jan 1, 2019. 
We identified a study that identified similar clusters in a Chinese 
population and a small mixed American population but that did 
not examine any aspect of clinical utility because clinical 
follow-up was not available. A second study of Danish patients 
applied a similar cluster analysis and, with duration of diabetes as 
an additional input variable, identified five subgroups of type 2 
diabetes that differed to those in the original study, and differed 
in the prevalence of diabetes complications. No studies were 
found that tested the clinical utility and the role in treatment of 
the proposed cluster-based approach.
Added value of this study
This study advances the concept of heterogeneity in type 2 
diabetes by testing the clinical utility of the data-driven cluster 
approach proposed by Ahlqvist and colleagues. The cluster 
analysis was repeated, and differences by cluster in disease 
progression and treatment response were assessed in newly 
diagnosed participants in the ADOPT trial with randomised, 
protocol-driven, follow-up data available. We found that the 
clusters were reproducible and differed in progression and 
treatment response. However, simple clinical measures were as 
or more useful than were the clusters for stratifying each 
outcome assessed.
Implications of all the available evidence
Patients with type 2 diabetes differ in treatment response and 
risk of disease progression, raising the possibility of a 
practical, stratified approach that is clinically orientated. 
Our study suggests a prediction model approach, combining 
phenotypic measures to predict specific outcomes for 
individual patients, is likely to have greater clinical utility 
than approaches that use clinical features to assign 
individuals to subgroups.
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BMI, and baseline HbA1c comprised the other measures 
required for cluster analysis.
Outcomes
Glycaemic progression was defined as the change in 
HbA1c from 1 year up to 5 years, thus allowing for an 
initial period of treatment response up to 1 year.
Chronic kidney disease was defined as progression from 
normal glomerular filtration rate (estimated glomerular 
filtration rate [eGFR] ≥60 mL/min per 1·73 m²) to 
confirmed chronic kidney disease stage 3 (two consecutive 
measures of eGFR <60 mL/min per 1·73 m²). eGFR was 
calculated using the chronic kidney disease epidemiology 
collaboration (CKD­EPI) equation;12 as a sensitivity analysis 
eGFR was calculated using the Modification of Diet in 
Renal Disease (MDRD) Study equation.13 Measures of renal 
function were recorded at baseline, 6 months, and annually. 
If progression was confirmed, the first of the two study 
visits was used to define chronic kidney disease onset. 
Albuminuria was defined as progression from normal 
urinary albumin to creatinine ratio (UACR, <30 mg/g) to 
either microalbuminuria (UACR 30–300 mg/g) or 
macroalbuminuria (UACR ≥300 mg/g). Individuals with 
eGFR lower than 60 mL/min per 1·73 m² were excluded 
from the analysis of chronic kidney disease and those with 
UACR 30 mg/g or more at their baseline visit were 
excluded from analysis of albuminuria outcomes.
Glycaemic response was defined as achieved HbA1c and 
as cumulative HbA1c reduction at 3 years, as measured by 
area­under­the­curve (3­year AUC HbA1c). AUC HbA1c is 
equivalent to the time­updated HbA1c measure used in the 
UK Prospective Diabetes Study outcomes model.14 3 years 
was chosen as the timepoint at which average AUC HbA1c 
was approximately equal between the three drugs.8 Other 
timepoints will tend to favour a specific therapy; early 
timepoints will favour sulfonylureas because these 
drugs have an increased short­term response, but 
later timepoints favour thiazolidinediones, which have 
increased glycaemic durability.8
Cluster analysis
In ADOPT, we repeated the clustering approach of 
Ahlqvist and colleagues.4 Men and women were 
clustered separately then pooled, continuous measures 
were mean centred and standardised, and continuous 
measures greater than five SDs from the mean were 
excluded. We applied K­means clustering specifying 
four clusters to the GADA­negative subset of individuals 
because K­means clustering does not incorporate 
binary variables; all GADA­positive individuals were 
manually assigned to a separate cluster.4 The same 
R command (kmeansrun), number of runs (100), and 
measure of cluster stability (Jaccard coefficient >0·75, 
after 2000 bootstraps) were applied.15 Once clusters 
were defined we assigned the same cluster names as in 
the original study, based on the distribution of cluster 
characteristics. In RECORD, we first assigned each 
individual to their ADOPT­derived cluster on the basis 
of their Euclidean distance from each cluster centre, 
and second, repeated the cluster analysis to derive 
RECORD­specific clusters. As GADA status was not 
available, all individuals in RECORD were assumed to 
be GADA­negative.
Statistical analysis
In both cohorts, mean HbA1c trajectories from rando­
misation up to 5 years for each cluster were first 
estimated using a repeated­measures mixed­effects 
model, including fixed effects for study visit, assigned 
cluster, and a study visit by cluster interaction. Patient­
level random effects and an unstructured covariance 
matrix were specified for this and subsequent mixed­
effects models. All individuals within a trial were pooled 
to assess progression, regardless of randomised therapy. 
To estimate glycaemic progression by cluster, the same 
model was then fitted but with HbA1c change from 1 year 
as the outcome. We estimated the mean annual rate of 
glycaemic progression for each cluster by updating the 
cluster model to replace study visit with time as a linear 
covariate. Mean HbA1c by age was estimated using the 
same model but with a linear term for continuous age at 
diagnosis replacing the clusters. For each model we 
estimated the proportion of variance explained (R²) by 
the fixed effects, Akaike information criterion, and the 
adequacy index.16,17
We compared the cumulative incidence of chronic 
kidney disease by cluster using Kaplan­Meier plots and 
both unadjusted and baseline eGFR (continuous linear 
term) adjusted Cox proportional hazard models with 
cluster as a categorical variable. We estimated R² and the 
discrimination ability (Harrell’s C­index) of the 
unadjusted cluster Cox model compared with a Cox 
model with continuous baseline eGFR as a linear term.17 
We repeated the same analysis for time to a 30% decline 
in eGFR, and for time to albuminuria with and without 
adjustment for baseline UACR as a continuous linear 
term. We also compared continuous relative changes 
from baseline in eGFR and UACR progression by cluster, 
using mixed­effects models with fixed effects for study 
visit, cluster, and study visit by cluster interaction.
We tested whether HbA1c response to the three drugs 
differed across the clusters in ADOPT. Average HbA1c 
trajectories by drug were estimated up to 3 years for each 
cluster separately, using repeated­measures mixed­
effects models with fixed effects for study visit, drug, visit 
by drug interaction, and visit by baseline HbA1c 
interaction. 3­year AUC HbA1c was estimated for each 
drug in each cluster as the integral of the area under the 
mean HbA1c trajectory, using the trapezoidal rule.
Treatment selection: clusters strategy vs clinical 
features strategy
We investigated whether clusters were more useful than 
simple clinical features to select a drug for individual 
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patients based on predicted 3­year AUC HbA1c. Models to 
predict HbA1c were developed in ADOPT using 
two strategies: (1) using the clusters and (2) using clinical 
features. For the clusters strategy, we estimated HbA1c 
response for each drug at the cluster level and applied 
this to all individuals within the cluster. This strategy 
treats individuals within a cluster as homogenous for 
treatment response to a particular drug. For the clinical 
features strategy, we combined sex and linear terms for 
age at diagnosis, baseline BMI, and baseline HbA1c (the 
four routine clinical features informing the clusters) in a 
multivariable model to estimate HbA1c response specific 
to each individual for each drug. The benefit of using 
each strategy developed in the ADOPT trial to select 
treatment for individuals was then tested in an external 
trial population, RECORD.
For the clusters strategy, 3­year AUC HbA1c for each 
drug was estimated at cluster level. For the clinical 
features strategy, 3­year AUC HbA1c was estimated for 
each individual on the basis of their precise clinical 
characteristics, using multivariable repeated­measures 
mixed­effects models for each drug. Each model had 
HbA1c up to 3 years as the outcome, with age at diagnosis, 
BMI, baseline HbA1c, and study visit by baseline HbA1c 
interaction as continuous linear terms, and study visit 
and sex as fixed effects. Model performance for each 
strategy was assessed using R².
The purpose of a treatment selection model is to select 
the most effective therapies for individual patients, and 
therefore improve outcome at a population level, rather 
than to predict drug response accurately. Therefore, the 
true test of a treatment selection model is whether it can 
robustly identify individuals who are likely to benefit 
from particular therapies.18 Standard model performance 
metrics test the ability of a model to predict the outcome 
and are therefore insufficient in this context.18,19
We therefore applied the following steps to test the 
effectiveness of each treatment selection strategy. For 
each individual in RECORD, we applied the models 
developed in ADOPT to obtain estimates of 3­year AUC 
HbA1c on each drug. In the clusters strategy, these 
predictions were according to the individual’s assigned 
cluster (the same for all individuals within a cluster). In 
the clinical features strategy, predictions were made at 
the individual level, estimated from precise clinical 
features. For each strategy, we applied a simple decision 
rule to assign individuals into two groups, one concordant 
and one discordant. Discordant individuals were those 
randomly assigned to a drug with a predicted 3­year AUC 
HbA1c that is 3 mmol/mol higher (ie, less improvement 
in HbA1c) than that of the drug predicted to be their best 
drug; all other individuals were defined as concordant.20 
The effectiveness of each treatment selection strategy 
was measured by the difference in 3­year AUC HbA1c 
between the concordant and discordant groups. 3­year 
AUC HbA1c by concordant or discordant group was 
estimated from a mixed­effects model with study visit, 
concordant or discordant group, baseline HbA1c, study 
visit by concordant or discordant group interaction, 
and visit by baseline HbA1c interaction as fixed effects. 
We tested the sensitivity of results to the HbA1c threshold 
used to define concordance by repeating the analysis at 
HbA1c thresholds of 0, 1, 2, and 4 mmol/mol. 
In RECORD, we compared the time to the trial primary 
outcome, cardiovascular hospitalisation or cardiovascular 
death, by cluster using unadjusted and baseline age­
adjusted Cox proportional hazard models.
To examine the utility of the original ANDIS clusters, 
we assigned individuals in ADOPT to their ANDIS cluster 
on the basis of their Euclidean distance from the cluster 
centres defined by Ahlqvist and colleagues.4 We estimated 
glycaemic and renal progression and HbA1c response for 
each ANDIS­derived cluster and compared model 
performance of the ADOPT defined clusters and ANDIS 
clusters. All analyses were done using R (version 3.4.1).
Role of the funding source
The funders had no role in the study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data and had final responsibility for the decision to 
submit for publication.
Results
We found that the clusters identified by Ahlqvist and 
colleagues were reproducible in trial populations. 
4003 individuals in ADOPT had valid baseline measures 
for cluster assignment. Of these, 3802 were in the 
intention­to­treat population and so were eligible for 
analysis of patient outcomes. We found a clear pattern of 
differences between clusters in clinical characteristics 
(figure 1A, appendix pp 3–5), and were able to assign the 
same cluster names as Ahlqvist and colleagues did 
(figure 1B). Clusters were reasonably stable (Jaccard 
mean range for men 0·76–0.82; for women 0·69–0·82). 
Cluster­centre coordinates are shown in the appendix 
(p 3). In RECORD, 4148 individuals were eligible for 
cluster assignment (4057 in the intention­to­treat 
population). RECORD clusters were similar to the 
ADOPT clusters whether they were assigned from 
ADOPT or defined de novo in RECORD (appendix p 6).
Average HbA1c trajectories by cluster from 
randomisation to 5 years are shown in the appendix (p 7). 
Glycaemic progression from 1 year differed by cluster in 
ADOPT (figure 2A), with a higher rate of progression in 
clusters 1 (SAID), 2 (SIDD), and 4 (MOD). In RECORD, 
only cluster 4 (MOD) had a higher rate of progression 
(appendix p 8). However, in both trials older age at 
diagnosis was associated with a lower rate of glycaemic 
progression (mean annual difference in rate of HbA1c 
change per year increase in age at diagnosis: (ADOPT 
−0·06 mmol/mol, 95% CI −0·07 to −0·05; RECORD 
−0·05 mmol/mol, 95% CI −0·06 to −0.04; figure 2B, 
appendix p 8). Age at diagnosis explained a similar 
See Online for appendix
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proportion of variation in progression to the clusters 
(ADOPT R²=0·09 age at diagnosis, R²=0·08 clusters; 
RECORD R²=0·05 age at diagnosis, R²=0·05 clusters). 
Other measures of model performance were also similar 
(appendix p 8).
We found differences in the incidence of chronic kidney 
disease between clusters after excluding patients with 
pre­existing chronic kidney disease; clusters 1, 3, and 5 had 
the highest incidence of chronic kidney disease (figure 3A, 
appendix p 9). However, there were differences between 
the clusters in baseline renal function: the clusters with 
the highest incidence of chronic kidney disease had the 
lowest baseline eGFR (appendix p 5). After adjustment for 
baseline eGFR there was no evidence of a difference in 
Figure 1: Cluster characteristics and cluster distribution in ADOPT
(A) Distributions of HbA1c, BMI, age at diagnosis, HOMA2-B, and HOMA2-IR at baseline for each cluster. (B) Distribution of ADOPT participants (n=4003) according to 
k-means clustering. SAID=severe autoimmune diabetes. SIDD=severe insulin-deficient diabetes. SIRD=severe insulin-resistant diabetes. MOD=mild obesity-related 
diabetes. MARD=mild age-related diabetes. HOMA2-B=homoeostatic model assessment 2 estimates of β-cell function. HOMA2-IR=homoeostatic model 
assessment 2 estimates of insulin resistance.
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time to chronic kidney disease across the clusters (table 1, 
appendix p 10). Results were similar using eGFR calculated 
using MDRD (appendix p 11). In ADOPT, baseline eGFR 
explained a greater proportion of variation (R²=0·18) and 
discrimination ability (C­statistic 0·90) than did the 
clusters (R²=0·01, C­statistic 0·58); these results were 
similar to those in RECORD (baseline eGFR R²=0·15, 
C­statistic 0·86; clusters R²=0·01, C­statistic 0·57). Relative 
change from baseline in eGFR and time to 30% decline in 
eGFR did not differ by cluster (appendix pp 12–15).
There was no clear pattern of difference between 
clusters in baseline UACR (appendix p 5), in incidence 
of albuminuria (figure 3B, appendix p 9), or in relative 
change in UACR (appendix p 15). After adjustment for 
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Figure 2: Glycaemic progression by cluster in ADOPT from 1 to 5 years
(A) HbA1c change by cluster (n=3016). (B) HbA1c change by age at diagnosis (10th, 50th, and 90th percentile of ADOPT participants. Data are estimates from repeated 
measures, mixed-effects models. SAID=severe autoimmune diabetes. SIDD=severe insulin-deficient diabetes. SIRD=severe insulin-resistant diabetes. MOD=mild 
obesity-related diabetes. MARD=mild age-related diabetes.
Figure 3: Renal progression by cluster in ADOPT over 5 years
(A) Cumulative incidence of chronic kidney disease stage 3 (confirmed eGFR <60 mL/min per 1·73 m²) in individuals with eGFR ≥60 mL/min per 1·73 m² at baseline 
(n=3694). (B) Cumulative incidence of albuminuria (UACR ≥30 mg/g) in individuals with UACR <30 mg/g at baseline (n=3168). eGFR=estimated glomerular filtration 
rate. UACR=urinary albumin to creatinine ratio. SAID=severe autoimmune diabetes. SIDD=severe insulin-deficient diabetes. SIRD=severe insulin-resistant diabetes. 
MOD=mild obesity-related diabetes. MARD=mild age-related diabetes.
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baseline UACR, time to albuminuria was shorter for 
cluster 3 (SIRD) versus cluster 2 (SIDD) in ADOPT, 
but not RECORD (table 1, appendix p 10). The 
clusters had no prediction and discrimination ability 
(ADOPT R²=0·00, C­statistic 0·52; RECORD R²=0·00, 
C­statistic 0·52); baseline UACR was a more useful 
measure (ADOPT R²=0·12, C­statistic 0·74; RECORD 
R²=0·10, C­statistic 0·73).
Patterns of HbA1c response to the different drugs 
differed across clusters in ADOPT (figure 4, appendix 
p 16). As defined by an HbA1c of greater than 3 mmol/mol 
compared with the other drugs, there was an overall HbA1c 
benefit with thiazolidinedione therapy in cluster 3 (SIRD), 
and for sulfonylurea therapy in cluster 5 (MARD; table 2). 
However, the combined clinical features explained more 
variation in response than did the clusters: R² was lower 
for the clusters strategy than for the clinical features 
strategy (In ADOPT, R² 0·15 for metformin, 0·20 
sulfonylureas, 0·17 thiazolidinediones for clusters 
strategy; R² 0·35 metformin, 0·33 sulfonylureas, 0·32 
thiazolidinediones for clinical features strategy).
In the independent validation cohort (RECORD) we 
found clinical features outperformed the clusters for 
treatment selection. In RECORD, we tested the 
performance for treatment selection of the two strategies 
developed in ADOPT (coefficients for the ADOPT clinical 
features model are given in the appendix [p 16]). Each 
individual in each trial was assigned as concordant or 
discordant with the treatment selection rule under both 
strategies (table 2, appendix pp 17–18).
In ADOPT, using both strategies, there was a greater 
overall HbA1c reduction in the concordant group 
compared with the discordant group (figure 5A). In 
RECORD, there was a greater benefit in the concordant 
group with the clinical features strategy than with the 
clusters strategy (figure 5B). The clinical features strategy 
outperformed the clusters at all HbA1c thresholds that 
were assessed to define concordant and discordant 
groups in RECORD (appendix p 19).
There was no evidence of differences between clusters 
in the risk of cardiovascular hospitalisation or death in 
RECORD after adjustment for age (appendix p 20). 
Clusters assigned to individuals in ADOPT using the 
cluster­centre coordinates in ANDIS were broadly similar 
to those defined de­novo in ADOPT (figure 1, appendix 
p 21). 58% of individuals were assigned to the same 
cluster using the ANDIS clusters and the ADOPT clusters 
(appendix p 21). Differences in outcomes by ANDIS 
cluster are shown in the appendix (pp 22–23). ADOPT 
clusters outperformed the ANDIS clusters for treatment 
response; model performance measures were similar for 
glycaemic and renal progression (appendix p 24).
Discussion
We found that the data­driven clusters of Ahlqvist and 
colleagues were reproducible in trial data. Clusters 
differed in glycaemic and renal progression but simple 
clinical features worked as well or better to predict disease 
progression (age at diagnosis for glycaemic progression 
and baseline renal function for renal progression). To our 
knowledge, for the first time we have shown differences 
by cluster in treatment response. However, clusters were 
Figure 4: Change in HbA1c by drug for clusters 2–5 in ADOPT over 3 years (n=3607)
Adjusted mean HbA1c over 3 years by drug. Shading shows 95% CIs. Data for cluster 1 (SAID; n=158) are shown in 
the appendix (p 16). SAID= severe autoimmune diabetes. SIDD=severe insulin-deficient diabetes. SIRD=severe 
insulin-resistant diabetes. MOD=mild obesity-related diabetes. MARD=mild age-related diabetes.
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Participants Person-years 
at risk
Events Unadjusted HR 
(95% CI)
HR (95% CI)
Time to CKD stage 3 (n=3694)
Cluster 1 (SAID) 155 499 6 2·82 (1·02–7·75) 1·56 (0·56–4·29)*
Cluster 2 (SIDD) 758 2262 10 1·00 (ref) 1·00 (ref)*
Cluster 3 (SIRD) 743 2501 22 2·05 (0·97–4·33) 1·11 (0·53–2·35)*
Cluster 4 (MOD) 808 2428 8 0·74 (0·29–1·88) 1·43 (0·56–3·63)*
Cluster 5 (MARD) 1230 4369 34 1·84 (0·91–3·73) 1·39 (0·69–2·82)*
Time to albuminuria (n=3168) 
Cluster 1 (SAID) 129 381 20 0·96 (0·59–1·55) 1·24 (0·76–1·52)†
Cluster 2 (SIDD) 642 1669 93 1·00 (ref) 1·00 (ref)†
Cluster 3 (SIRD) 637 1781 121 1·23 (0·94–1·62) 1·32 (1·01–1·73)†
Cluster 4 (MOD) 652 1630 108 1·19 (0·90–1·56) 1·27 (0·96–1·67)†
Cluster 5 (MARD) 1108 3428 183 0·98 (0·76–1·26) 1·18 (0·92–1·52)†
*Adjusted for baseline eGFR. †Adjusted for baseline UACR. HR=hazard ratio. eGFR=estimated glomerular filtration rate. 
CKD=chronic kidney disease. SAID=severe autoimmune diabetes. SIDD=severe insulin-deficient diabetes. SIRD=severe 
insulin-resistant diabetes. MOD=mild obesity-related diabetes. MARD=mild age-related diabetes. UACR=urinary 
albumin to creatinine ratio.
Table 1: Risk of renal progression by cluster in ADOPT
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markedly outperformed by models that used simple 
clinical features for the prediction of glucose­lowering 
response and for treatment selection. Overall, the results 
suggest that there will be greater clinical utility from 
modelling clinical features directly, rather than from 
using clinical features to place patients into subgroups 
(appendix p 25).
Although there were restricted eligibility criteria for the 
ADOPT and RECORD trials, subgroups defined by 
cluster analysis were similar to those seen in non­
selective Scandinavian cohorts, and subsequently 
Chinese and US cohorts.4,21 This similarity suggests that 
if the cluster analysis is repeated in the specified way in 
new datasets it will routinely produce similar clusters.
A key strength of trial data over previous observational 
data is the availability of protocol­driven follow­up, 
meaning that we were able to do a systematic assessment 
and show that the clusters differ in disease progression. 
This possibility is a considerable advantage over routine 
follow­up, in which therapy introduction is not protocol 
driven.4 Independently of therapy, clusters 1 (SAID), 
2 (SIDD), and 4 (MOD) had an increased rate of glycaemic 
progression. Differences in the development of renal 
failure had previously been shown in observational 
follow­up, and we replicated a faster progression of renal 
disease in clusters 3 (SIRD) and 5 (MARD), although 
there was no evidence of a difference in renal progression 
after accounting for baseline renal function.
We established that the clusters differ in response to 
different glucose­lowering therapies. This finding was 
possible because of the randomised, systematic therapy 
given. We found a particular benefit for cluster 3 (SIRD) 
with thiazolidinediones, and for cluster 5 (MARD) with 
sulfonylureas.
The fact that clusters are reproducible and can help to 
predict progression and response to therapy is important. 
However, a key question raised in response to the original 
article is whether it is more clinically useful to use clinical 
features to assign a patient to a subgroup and then treat in 
a way that is best for that subgroup, or to use clinical 
features to predict patient outcomes directly using 
outcome­specific models.7 We found that simple clinical 
features were similar to or better than the clusters to 
stratify disease progression and to personalise therapy. A 
simple model incorporating only age at diagnosis was able 
to predict glycaemic progression as well as the clusters, 
having been identified as a key predictor of progression in 
an observational analysis.22 Similarly, baseline renal 
function explained differences between the clusters in risk 
of renal progression.
For treatment response we found that models combining 
four simple clinical measures (age, sex, baseline HbA1c, 
and BMI) explained more variation in response than did 
the clusters. However, this finding gives little insight into 
whether a strategy based on the clusters model or on a 
continuous features model is more useful to select between 
treatment options for an individual patient.18,19 A more 
useful test in this context is to compare the population­level 
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Figure 5: Change in HbA1c over 3 years in concordant and discordant treatment selection groups
(A) ADOPT development cohort (n=3785), clusters strategy (left panel) and clinical features strategy (right panel). 
(B) RECORD validation cohort(n=4057), clusters strategy (left panel) and clinical features strategy (right panel).
Cluster 1 (SAID), n=158 Cluster 2 (SIDD), n=759 Cluster 3 (SIRD), n=775 Cluster 4 (MOD), n=811 Cluster 5 (MARD), n=1262
Metformin −15·6 (−23·7 to −7·4)* −35·7 (−39·9 to −31·6)* −16·1 (−18·7 to −13·5) −15·9 (−19·4 to −12·3)* −12·8 (−14·5 to −11·0)
Sulfonylurea −7·8 (−18·4 to 2·7) −33·3 (−37·6 to −29·1)* −15·3 (−18·1 to −12·5) −11·2 (−14·7 to −7·7) −16·1 (−17·9 to −14·3)*
Thiazolidinediones −9·6 (−19·5 to 0·3) −31·6 (−35·8 to −27·5) −19·2 (−21·8 to −16·6)* −15·3 (−18·6 to −12·0)* −9·1 (−10·9 to −7·4)
Estimated as HbA1c area under the curve (AUC [mmol/mol]) at 3 years (95% CI) from repeated measures mixed models. SAID=severe autoimmune diabetes. SIDD=severe 
insulin-deficient diabetes. SIRD=severe insulin-resistant diabetes. MOD=mild obesity-related diabetes. MARD=mild age-related diabetes. *Individuals within the cluster 
randomised to drug are classified as concordant under the clusters strategy treatment selection rule: best drug for the cluster or 3-year AUC HbA1c difference ≤3mmol/mol 
compared with best drug for the cluster. 
Table 2: Cumulative HbA1c reduction at 3 years by drug for each cluster in ADOPT
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effect of applying each strategy to select treatment on 
glycaemic response,19 which we were able to directly assess, 
by comparing the two strategies developed in ADOPT in 
an independent trial dataset (RECORD). This comparison 
was possible because some participants in RECORD were 
randomly assigned to the drug estimated to be best for 
them on the basis of the ADOPT models (concordant 
group), and the remainder were randomly assigned to a 
drug that was not best (discordant group). The difference 
in HbA1c between the two groups provided a measure of 
the population­level effect of each treatment selection 
strategy. In RECORD, we found a small benefit (1·8 mmol/
mol over 3 years) of selecting therapy by cluster; by 
contrast, there was a greater benefit (3·9 mmol/mol) 
selecting treatment using the clinical features model 
(difference in 3­year HbA1c; figure 5B). These results 
suggest that attempts to personalise treatment in type 2 
diabetes will have the most clinical utility if they are based 
on the use of continuous phenotypic measures, rather 
than on subgroup assignment.
Strengths of this study include the use of data from 
two large, long­term, randomised trials, in which we were 
able to not only reproduce the clustering approach of 
Ahlqvist and colleagues, but also to describe diabetes 
progression and treatment response in protocol­driven 
follow­up. Furthermore, we were able to test treatment 
selection based on clusters compared with clinical 
features in an independent validation dataset. The 
treatment selection rule we applied was designed to test 
clinical utility in this study, rather than to maximise 
outcomes for the population or individuals. Approaches 
to assess treatment selection strategies are not well 
developed and are the subject of ongoing methodological 
research.18 A limitation of our study is the potential non­
representativeness of participants due to the original trial 
exclusion criteria. Both ADOPT and RECORD had 
exclusion criteria based on blood glucose levels and age 
(and BMI in RECORD); these clinical variables informed 
the cluster analysis. Despite these criteria, we found that 
the clusters were reproducible, with a pattern of 
differences in phenotypic measures that closely matched 
those previously reported. Given the variables informing 
the cluster analysis are not independent and are likely to 
be similarly correlated in most patients with diabetes, this 
reproducibility is not surprising,7 although similarly to 
the original study, we had little data on non­white 
ethnicities (ADOPT was 88% white, RECORD was 99%). 
Because of the design of the trials we were unable to 
assess some outcomes explored in the original study, 
such as time to insulin, and we did not have power to 
assess other outcomes, including development of end­
stage renal disease. A further limitation was the therapy 
used in the trials; assessment of heterogeneity in 
treatment response for the drug classes dipeptidyl 
peptidase inhibitors, sodium­glucose co­transporter­2 
inhibitors, and glucagon­like peptide­1 receptor agonists 
would be of considerable interest.
An important difference between this study and the 
study by Ahlqvist and colleagues is in the analysis of 
renal progression. Although we excluded individuals 
with pre­existing kidney disease, in the Scandinavian 
population­based cohorts people with pre­existing kidney 
disease when diagnosed with diabetes were not excluded 
and the onset of renal dysfunction was set to the first 
time that an abnormal value was found in clinical testing 
after diagnosis.
Precision medicine is successfully established in 
monogenic and neonatal diabetes, in which defining 
discrete aetiological subtypes with differing genetic causes 
that have different optimal treatment require ments has 
been possible.23–25 A key difference from type 2 diabetes is 
that the monogenic and neonatal diabetes subgroups 
identified have discrete and non­overlapping aetiologies 
and can be robustly defined by genetic sequencing. By 
contrast, the study by Ahlqvist and colleagues and other 
attempts to characterise the heterogeneity in type 2 
diabetes have identified clusters with poor clinical utility 
because the clusters are non­aetiological, overlapping, 
highly dependent on the variables used to classify them, 
and cannot be robustly defined at an individual level.4,26 
Even genetic susceptibility clusters, which do have the 
advantage of being fixed throughout life, have not led to 
the identification of discrete aetiological subtypes of type 2 
diabetes, although such clusters offer insight into 
mechanistic pathways underlying heterogeneity.27
The known heterogeneity in type 2 diabetes, together 
with the differences we have observed in clinical outcomes, 
raises the possibility of a practical clinical application of 
precision medicine in type 2 diabetes in the near future. 
Our study supports the suggestion that the optimal 
approach to tailor management on the basis of risk of 
progression and therapeutic response will be to use 
phenotypic measures to predict specific outcomes for 
individuals using multivariable models, rather than define 
subgroups and assume all individuals are homogeneous 
within each subgroup.7 In particular, specific clinical 
characteristics have been shown to have robust 
associations with response to specific type 2 diabetes drug 
options.6,28–30 These studies raise the possibility that the 
relative glucose­lowering benefit of the different drugs 
might be identifiable by combining simple clinical 
measures in a model for treatment selection. Testing this 
possibility will require systematic assessment of 
associations between other patient features (including 
lifestyle factors, biomarkers, and concomitant 
medications) beyond those assessed in this study. The 
advantage of such an approach is that the clinical features 
used are already part of routine clinical care. Similarly, 
further systematic assessment of associations between 
clinical patient features and glycaemic and renal 
progression will be required to see whether individuals at 
high or low risk of progression can be robustly identified.
The methodology we have applied in this study, 
harnessing existing trial data at an individual level to test a 
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precision medicine strategy developed in other data, offers 
an exciting, low­cost framework to assess novel precision 
medicine approaches without a prospective trial. Such trial 
datasets are increasingly available to researchers to answer 
secondary research questions.31 The approach we used 
of a direct comparison of different approaches in an 
independent dataset is a good model for defining the 
relative performance of such approaches. When defining 
the utility of models in future studies it will be important 
to examine multiple relevant outcomes as well as 
glycaemia, including cardiovascular outcomes, micro­
vascular complications, and non­glycaemic effects of 
specific drugs, including weight change and side­effects.
In conclusion, we have shown that cluster­defined 
subgroups are reproducible and can help to define 
individuals that vary in the risk of diabetes progression 
and in glycaemic response to common therapeutic 
options. Our study shows that a prediction model 
approach combining phenotypic measures to predict 
specific outcomes for individual patients is likely to have 
greater clinical utility than is subgroup assignment. 
Existing trial data offer an exciting opportunity to evaluate 
the potential of precision medicine approaches to improve 
patient outcomes in type 2 diabetes.
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